Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Truetiva, Inc. operates in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is assigned to 1 distinct examiner and 1 distinct art unit. This indicates a singular focus in the company's current patent prosecution, with all activity concentrated on 1 specific matter.
CHANG, KYUNG SOOK is the busiest examiner for the portfolio, responsible for 1 pending office action. Current prosecution is focused on this 1 examiner, allowing for a streamlined communication process. The company does not have to manage multiple conflicting timelines or different examiner preferences across its current pending matters.
The use of 1 distinct art unit suggests that the technology being patented is highly specialized within the biotechnology and pharmaceutical field. Practitioners can focus their strategy on the specific examination trends of this 1 unit and examiner. Although the portfolio currently has only 1 pending action, the centralized nature of the prosecution provides a clear focus for the company's immediate patenting goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19068891 | ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAME | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19068891 | ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAME | CHANG, KYUNG SOOK | 1613 | §103DP | Non-Final OA | — | Pending | Mar 03, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTruetiva, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyung Sook Chang has the most, with 1 of Truetiva, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.